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Abstract: Surface modification of nanocarriers with amphiphilic polymer polyethylene 
glycol (PEG), known as PEGylation, is regarded as a major breakthrough in the application 
of nanocarriers. However, PEGylated nanocarriers (including liposomes and polymeric 
nanoparticles) induce what is referred to as the “accelerated blood clearance (ABC) phenomenon” 
upon repeated injection and consequently they lose their sustained circulation characteristics. 
Despite this, the present authors are not aware of any reports of accelerated clearance due to 
repeated injection for PEGylated solid lipid nanoparticles (SLNs), another promising nanocarrier. 
This study investigated the pharmacokinetics of PEGylated SLNs upon repeated administration 
in mice; moreover, the impact of circulation time on the induction of the ABC phenomenon was 
studied in beagles for the first time. The ABC index, selected as the ratio of the area under the 
concentration-time curve from time 0 to the last measured concentration of a second injection 
to that of the first injection, was used to evaluate the extent of this phenomenon. Results showed 
that the PEGylated SLNs exhibited accelerated clearance from systemic circulation upon 
repeated injection, both in mice and in beagles, and the ratio for the different time intervals, 
which showed that the ABC index exhibited significant difference within 30 minutes following 
the second injection, was good enough to evaluate the magnitude of ABC. This ABC index 
indicated that the 10 mol% PEG SLNs with a suitable prolonged circulation time induced the 
most marked ABC phenomenon in this research. This study demonstrated that, like PEGylated 
nanocarriers such as liposomes and polymeric nanoparticles, PEGylated SLNs induced the 
ABC phenomenon upon repeated injection – the beagle was a valuable experimental animal 
for this research. Furthermore, the authors considered that a relatively extended circulation 
time of the initial dose may be the underlying major factor determining the induction of the 
ABC phenomenon.
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Introduction
Nanomedicine, the medical application of nanotechnology, holds considerable 
promise as far as drug delivery systems are concerned. Over the last few decades, 
there has been dramatic development of nanocarriers in nanomedicine, including 
liposomes, polymersomes, and polymeric nanomicelles, opening up new possibilities 
for cancer imaging, molecular diagnosis, and targeted therapy.1 Surface modification 
of nanocarriers with amphiphilic polymer polyethylene glycol (PEG), known as 
PEGylation, is regarded as a major breakthrough in the application of nanocarriers.2 
It is widely believed that the steric stabilization provided by PEG polymers confers a 
relative “invisibility” to the nanocarriers, which is reflected in a reduced recognition 
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by the mononuclear phagocyte system and a prolonged 
blood circulation time; because of this, the PEGylated 
nanocarriers have attracted increasing attention.3–5 However, 
it has recently been reported that some PEGylated liposomes 
produce an unexpected phenomenon: PEGylated liposomes 
including PEGylated cationic liposomes containing 
nucleic acids have been found to lose their long-circulating 
characteristics upon repeated administration at certain time 
intervals in the same animal (referred to as the “accelerated 
blood clearance [ABC] phenomenon”).6–12 Furthermore, it 
is worth noting that this phenomenon was triggered by pre-
administration with not only PEGylated liposomes but also 
PEG-containing polymeric nanoparticles8,9 and polymeric 
micelles.10,13 These results imply that this unexpected 
phenomenon, being a potential challenge for PEGylated 
nanocarrier applications, would greatly compromise the 
benefits of nanoparticles during cancer diagnosis and drug 
or gene-mediated therapy.
Solid lipid nanoparticles (SLNs) have been used as a new 
colloidal carrier since 1991.14 Given the low intrinsic toxic-
ity and the biodegradability of the lipids used in SLNs, as 
well as the increased drug stability and the controlled drug 
release, it is not surprising that this relatively new class of 
drug carriers is quickly being adopted for the delivery of a 
variety of antineoplastic agents.15–18 The SLN systems have 
also been shown to cross the blood–brain barrier15–17 and 
to bypass the resistance mechanism involved in multidrug 
resistance19–22 – therefore, they have unique advantages as 
drug carriers in cancer therapy. It is expected that modified 
SLNs with PEG derivatives will be developed and used to 
take advantage of these properties. However, in view of the 
ABC phenomenon induced by PEGylated nanocarriers, study 
of the pharmacokinetics of PEGylated SLNs upon repeated 
administration is of great importance. For this research, anti-
cancer drugs cannot be used as model drugs – this is because 
of their toxic effects on the involved immune system.23–26 
Therefore, tocopheryl nicotinate (TN) was employed as an 
indicator in the present study by virtue of its lack of effect 
on the immune organs. Moreover, TN can be incorporated 
into SLNs with a high payload and stability, which helps to 
mimic the actual elimination of SLNs.
The ABC phenomenon has already been widely reported 
in mice,27 rats,28,29 rabbits,30 and rhesus monkeys.7 Instead 
of these animals, the beagle was selected as the primary 
experimental subject in the present study. This was because 
of the beagle’s relatively high blood volume, meaning 
collecting many blood samples over a short period time has 
little effect on physical function, and it is easy to monitor 
possible reactions throughout the entire experimental process. 
Both of these points were of great benefit for the ABC 
investigations undertaken.
The prolonged blood circulation time is the most 
important characteristic of PEGylated nanocarriers; however, 
despite extensive studies on the ABC phenomenon, it is still 
not clear whether the circulation time affects the induction 
of ABC. In the current study, the authors first investigated 
whether the ABC phenomenon was induced by repeated 
injection of PEGylated SLNs in mice. Following this, the 
ratio of AUC(0–t) (ie, area under the concentration-time curve 
from time 0 to the last measured concentration) for the second 
injection to that of the first one was selected as the ABC 
index, used to evaluate the effects of circulation time on the 
induction of the ABC produced in beagles.
Material and methods
Material
Glycerol monostearate (Sigma-Aldrich, St Louis, MO) was 
used as the matrix for the SLNs. Injectable soybean lecithin 
(S75) was purchased from Lipoid GmbH (Ludwigshafen, 
Germany) and N-(Carbonyl-methoxypolyethyl-eneglycol-
2000)-1,2-distearoyl-sn-glycero-3-phosphoethanolamine 
(mPEG2000-DSPE) was purchased from Genzyme Corporation 
(Cambridge, MA). TN was purchased from Northeast 
Pharmaceutical Group Co, Ltd (Shenyang, Liaoning, China). 
Sephadex® G-50 medium was supplied by Sigma-Aldrich. 
The ethanol was of pharmaceutical grade; all other reagents 
were of chromatographic grade.
Animals
Male Kunming mice (each weighing 20–25 g) and male 
beagles (each weighing 10–12 kg) were purchased from 
the Laboratory Animal Center of Shenyang Pharmaceutical 
University (Shenyang, Liaoning, China). All animal care 
and experiments were carried out in accordance with the 
guidelines of the Animal Welfare Committee of Shenyang 
Pharmaceutical University.
Preparation of the PEGylated SLNs
The melt-emulsification process was used to make the SLNs. 
Briefly, glycerol monostearate, S75, mPEG2000-DSPE, and TN 
were mixed and dissolved in ethanol at 65°C and the solvent 
was then removed. The melted mixture was then dispersed in 
5% glucose solution, under mechanical agitation, to achieve a 
final phospholipid (S75 and mPEG2000-DSPE) concentration of 
5 µmol ⋅ mL−1. The warm primary emulsion was further treated using 
a laboratory ultrasonic cell pulverizer (JY92-II; Ningbo Scientz 
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Biotechnology Co, Ltd, Ningbo, Zhejiang, China), for at least 
a 2-minute cycle (200 w) and an additional 3-minute cycle 
(400 w). Following sonication, to ensure homogeneity in size, the 
suspensions were then passed through polycarbonate membranes 
with a pore size of 0.22 µm. The components of each formulation 
are presented in Table 1.
Determination of encapsulation efficiency
The untrapped TN was removed by size exclusion 
chromatography, using a Sephadex G-50 mini-column 
(10 × 70 mm) with double-distilled water as the eluant. 
Briefly, 100 µL of SLN suspension was loaded onto the 
Sephadex G-50 mini-column and then eluted with 100 µL 
of double-distilled water four times. The concentration 
of TN in the SLNs was determined by high-performance 
liquid chromatography (HPLC) after dissolving the SLNs 
obtained from gel chromatography in methanol. The HPLC 
conditions were the same as for the method described for 
the pharmacokinetics studies. Encapsulation efficiency of 
the SLNs was calculated as the percentage of TN remaining 
in the SLNs following elution.
Determination of the incorporated ratio 
of mPEG2000-DSPE in SLNs
The ultrafiltration method was employed to separate 
mPEG2000-DSPE not incorporated into SLNs. Free mPEG2000-
DSPE was separated by passing the SLN suspension 
through the stirred ultrafiltration cells (Merck Millipore, 
  Billerica, MA), and the molecular weight cutoff of the 
ultrafiltration membrane (Shanghai Yadong Resin Co, Ltd, 
Shanghai, China) was 100 kDa. The amount of mPEG2000-
DSPE was determined according to Shimada et al’s31 
procedure, with some modifications.32 Briefly, 10 mL of 
sodium nitrate-picrate solution (sodium nitrate 3.33 mol ⋅ L−1, 
picric acid 0.02 mol ⋅ L−1, and sodium hydroxide 0.1 mol ⋅ L−1) 
and 5 mL of dichloromethane were added one by one to 5 mL 
of sample solution. The mixture was vortexed for 1 minute and 
then centrifuged at 3500 rpm for 15 minutes; following this, 
the organic layer was collected and spectrophotometrically 
measured at 365 nm (UV-1801; Beijing Rayleigh   Analytical 
lnstrument Corporation, China). The total amount of 
mPEG2000-DSPE in the formulation was determined using the 
same analytical procedure. The amount of mPEG2000-DSPE in 
the sample solution was calculated from the calibration curve 
of the standard mPEG2000-DSPE solution.
Measurement of particle size  
and zeta potential
The mean particle size and zeta potential of the SLNs 
were determined in purified water at 23°C by the dynamic 
light scattering method, using a submicron particle 
sizer (Nicomp® 380; Particle Sizing Systems, Inc, Santa 
Barbara, CA). The zeta potential was calculated from the 
electrophoretic mobility, using the Smoluchowski equation.
Biodistribution of the second dose  
of PEGylated SLNs in mice
The male Kunming mice were randomly divided into four 
groups of five: a control group and three treated groups. For 
the initial injection, the control mice were given 5% glucose 
solution and the treated mice were injected with 5, 10, and 
20 mol% PEG SLNs at a dose of 10 µmol phospholipids ⋅ kg−1 
via the tail vein separately. Seven days later, all the groups 
received 10 mol% PEG SLNs (10 µmol phospholipids ⋅ kg−1). 
The detailed injection scheme is presented in Table 2. At 
specified time points following the second injection, blood 
was collected, the mice were sacrificed, and samples of 
liver and spleen were removed. The blood samples were 
centrifuged at 4000 rpm for 10 minutes to separate the 
plasma. Plasma and tissue samples were stored at −20°C 
until analysis.
Pharmacokinetics of the second dose  
of PEGylated SLNs in beagles
The beagles were randomly divided into three groups of 
three, and for the first injection, the beagles were given 
Table 1 Components of each formulationa
Composition 5 mol% PEG SLNs 10 mol% PEG SLNs 20 mol% PEG SLNs
GMS (mg) 100.0 100.0 100.0
S75 (mg) 37.1 35.2 31.2
mPEG2000-DSPE (mg) 7.0 14.0 28.0
TN (mg) 20.0 20.0 20.0
5% glucose (mL) 9.8 9.8 9.8
Note: aIn each formulation, the molar ratio of total phospholipid (S75 and mPEG2000-DSPE) was fixed: S75: mPEG2000-DSPE = (1 − x): x (with x being 0.05, 0.1, or 0.2). 
Abbreviations: GMS, glycerol monostearate; mPEG2000-DSPE, N-(carbonyl-methoxypolyethylene-glycol-2000)-1,2-distearoyl-sn-glycero-3-phosphoethanolamine; S75, injectable 
soybean lecithin; TN, tocopheryl nicotinate; SLN, solid lipid nanoparticle.
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SLNs modified with different PEG surface densities at a 
dose of 2 µmol phospholipids ⋅ kg−1 via a vein in the right 
forelimb. Blood was collected from the same limb at selected 
time points using disposable cannulae. Seven days after the 
first injection, the beagles received a second injection in 
the same manner as the first injection and blood samples 
were collected as before. Pharmacokinetic parameters were 
calculated using DAS software (v 2.0; DAS Software, Inc, 
Kingston, Ontario, Canada). The detailed injection scheme 
is presented in Table 2.
The concentrations of TN in plasma and tissue samples 
were assayed by HPLC. The analysis system was equipped 
with a P230 pump and a UV230 ultraviolet and visible 
spectrophotometer (Dalian Elite Analytical Instruments Co, Ltd, 
Dalian, Liaoning, China), operated at 264 nm, and a Hypersil® 
BDS C18 column (Thermo Fisher Scientific, Waltham, MA, 
200 × 4.6 mm) filled with particles 5 µm in diameter. The 
mobile phase was methanol/isopropanol (80/20, v/v), the flow 
rate was 1 mL ⋅ min−1 at 30°C and the limit of quantitation was 
0.04 µg ⋅ mL−1. The linearity was excellent over the range of 
0.5–100 µg ⋅ mL−1 (r = 0.9962, n = 8 for beagles and r = 0.9990, 
n = 8 for mice). It was shown that the extractive recoveries 
were from 93.45% to 104.73% and the precision and accuracy 
of this HPLC method met the measurement requirements. 
Samples of plasma and tissue were treated as follows: 100 µL 
of methanol, 100 µL of internal standard (tocopheryl acetate), 
and 600 µL of n-hexane were added to 100 µL of plasma or 
homogenates (equivalent to 0.1 g tissue). The mixture was 
vortexed for 5 minutes and then centrifuged at 10000 rpm for 
10 minutes; following this, 500 µL of supernatant was collected 
and dried using a CentriVap® Centrifugal Vacuum Concentrator 
(Labconco Corporation, Kansas City, MO).   Following 
exsiccation, the dried material was mixed with 100 µL of 
mobile phase, vortexed for 1 minute, and then centrifuged at 
10000 rpm for 10 minutes; the supernatant was analyzed using 
a sample injection volume of 20 µL.
Detection of anti-PEG immunoglobulin M 
antibody in beagle serum
It has been proposed that the anti-PEG immunoglobulin M 
(IgM) produced by the initial dose was responsible for the ABC 
phenomenon.23,26,30 So, to examine the ability of PEGylated 
SLNs to generate anti-PEG IgM, serum samples were 
collected 7 days after a single dose of PEGylated SLNs and 
24 hours following the second injection, while the serum 
collected before the first injection was used as a control. 
Anti-PEG IgM was then determined according to a slightly 
modified previously published procedure.24 Briefly, 10 nmol 
mPEG2000 -DSPE in 50 µL of 100% ethanol was added to 
each well of a 96-well microplate (Corning Incorporated, 
New York, NY) and thoroughly air-dried. Wells were 
then blocked with 100 µL of 1% bovine serum albumin 
(Biosharp, Korea) in 50 mM Tris-buffered saline (pH 8.0) 
for 30 minutes. The wells were then washed five times 
with Tris-buffered saline (Sigma-Aldrich, St Louis, MO) 
containing 0.05% Tween® 20 (Sigma-Aldrich, St Louis, MO). 
Diluted serum samples (1:200 dilution in 1% bovine serum 
albumin/0.05% Tween 20/Tris-buffered saline) (100 µL) 
were then applied to the wells, followed by incubation for 
30 minutes and washing five times, as previously described. 
Horseradish peroxidase–conjugated goat anti-dog IgM 
antibody (100 µL, 1 µg ⋅ mL−1, goat anti-dog IgM was 
purchased from Immunology Consultants Laboratory, 
Inc, Oregon, USA, then the antibody was conjugated with 
HRP by Beijing Biosynthesis Biotechnology Co, Ltd, 
Beijing, China) was added to each well. After a 30-minute 
incubation, the wells were washed five times, as previously 
described. Staining was carried out by the addition of 100 µL 
of o-phenylenediamine (1 mg ⋅ mL−1) from Sigma-Aldrich. 
After a 5-minute incubation period, the reaction was stopped 
by adding 100 µL of 2 N sulfuric acid, and the absorbance 
was measured at 490 nm using a microplate reader (Bio-Rad 
Laboratories Ltd, Hemel Hempstead, Hertfordshire, United 
Kingdom). All incubations were performed at 25°C.
Statistical analysis
All mean values are expressed as mean plus or minus standard 
deviation. Statistical analysis was performed by Student’s 
t-test using SPSS software (SPSS, Inc, Chicago, IL). 
A P-value ,0.05 was considered statistically significant.
Results
The characteristics of PEGylated SLNs
It has been reported that the in vivo characteristics 
of nanocarriers may be influenced by many factors 
Table  2  Injection  scheme  of  the  PEGylated  solid  lipid  nano-
particles (SLNs)
Experimental  
animal
First treatment Second treatment
Mouse 5% glucose solution 10 mol% PEG SLNs
5 mol% PEG SLNs
10 mol% PEG SLNs
20 mol% PEG SLNs
Beagle 5 mol% PEG SLNs 5 mol% PEG SLNs
10 mol% PEG SLNs 10 mol% PEG SLNs
20 mol% PEG SLNs 20 mol% PEG SLNs
Abbreviation: PEG, polyethylene glycol.
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including composition, particle size, and zeta potential.33,34 
Therefore, the SLNs used for the present study needed to 
be fully characterized. The authors prepared three kinds of 
SLNs – containing 5, 10, and 20 mol% mPEG2000-DSPE, 
respectively. The mean particle size of the prepared SLNs was 
120–130 nm, with a zeta potential of approximately −20 mV . 
All the SLN formulations were sterilized by autoclaving 
at 100°C at 0.45 bar for 30 minutes, and the SLNs were 
physically stable during sterilization. Details with regard 
to the pharmaceutical properties of the prepared SLNs are 
summarized in Table 3.
The incorporated ratio of mPEG2000-DSPE 
in SLNs
The PEG surface density is reported to play an important 
role in inducing the ABC phenomenon. The present authors 
determined the incorporated ratio of mPEG2000-DSPE in SLNs 
by the picrate method. The calibration curve for the standard 
mPEG2000-DSPE solution was A = 0.00861C + 0.0971 in 
the range of 3–36 µg ⋅ mL−1 (r = 0.9935; n = 8; where A is 
absorbance and C is mPEG2000-DSPE concentration), and the 
incorporated ratios of 5,10, and 20 mol% PEG SLNs were 
90.21% ± 7.20%, 92.93% ± 5.44%, and 89.37% ± 4.01%, 
respectively. These results indicate that almost all of the 
mPEG2000-DSPE was incorporated into the SLNs.
Biodistribution of the second dose  
of PEGylated SLNs in mice
At present, most ABC studies are performed in mice or 
rats; therefore, the authors initially investigated the ABC of 
PEGylated SLNs in mice.
As shown in Figure 1, PEGylated SLNs injected weekly 
dramatically influenced the blood clearance in mice. SLNs 
containing 10 mol% PEG produced a higher elimination rate 
and more hepatic and splenic uptake of the second dose than 
with the other two formulations (Figure 2). For 10 mol% 
PEG SLNs, the biodistribution 30 minutes after the second 
dose showed a significantly reduced plasma concentration 
(from 71.30% ± 9.36% to 42.56% ± 9.69% of the injected 
dose) and, concomitantly, a higher accumulation in the liver 
(from 5.35% ± 0.43% to 23.29% ± 2.78% of the injected 
dose) (Figure 2A). Significant accumulation of the second 
dose was also observed in the spleen (Figure 2B), although it 
was substantially lower than in the liver. These results clearly 
indicate that the PEGylated SLNs were able to induce the 
ABC phenomenon.
Effect of circulation time on the ABC 
phenomenon induced in beagles
Reports have shown that the PEG surface density affects 
the induction of the ABC phenomenon.29 Furthermore, the 
  present authors’ results from mice also indicate that the 
amount of PEG lipid presented in the SLNs plays an important 
role in the induction of the ABC phenomenon. The authors 
speculated that varying circulation times of the initial dose 
were a result of different PEG surface densities and that this 
was the underlying factor in the induction of the different 
ABC phenomena. Thus, to further investigate whether a long 
circulation time is required to induce the enhanced clearance 
effect, the authors selected the beagle as the experimental 
animal – it was helpful to study the pharmacokinetics of the 
two doses in the same animal.
The beagles were first treated with SLNs containing 
5, 10, and 20 mol% mPEG2000-DSPE, at a dose of 2 µmol 
phospholipids ⋅ kg−1, and the same dose was also administered 
7 days later. As shown in Table 4, PEGylated SLNs exhibited 
a gradually increased circulation time with increasing PEG 
surface density; Figure 3 shows that all kinds of PEGylated 
SLNs induced the ABC phenomenon in beagles.
Conventionally, subsequent doses are identical to allow 
for investigation of the influence of the first injection. 
Table 3 Physicochemical parameters of solid lipid nanoparticles (SLNs) before and after sterilization
Physicochemical parameter 5 mol% PEG SLNs 10 mol% PEG SLNs 20 mol% PEG SLNs
Average diameter (nm)
  Before    138.0 ± 2.9    131.5 ± 4.1   130.5 ± 7.8
  After    132.5 ± 3.8    127.5 ± 3.9   119.3 ± 5.5
Zeta potential (mV)
  Before −27.13 ± 3.0 −21.78 ± 2.4 −16.98 ± 1.9
  After −28.52 ± 2.4 −22.65 ± 3.8 −17.66 ± 3.5
EE%
  Before    95.32 ± 2.58    94.42 ± 1.09   97.21 ± 1.38
  After    90.97 ± 4.82    91.32 ± 3.21   93.21 ± 2.01
Abbreviations: EE%, encapsulation efficiency; PEG, polyethylene glycol.
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30 minutes after readministration and these included lethargy, 
licking of lips, lachrymation, labored respiration, and nausea, 
which are typical of an Ab-mediated anaphylactic reaction.35 
Establishment of hypersensitivity might suggest the ABC 
phenomenon was induced to a certain degree, while it seemed 
there was no direct relationship between the duration of the 
symptoms and the intensity of this phenomenon. The authors 
also measured the serum levels of IgM antibodies reactive to 
PEG in the beagles after injection of PEGylated SLNs. The 
results indicate that after an initial priming dose of PEGylated 
SLNs, each of the formulations led to production of anti-PEG 
IgM to different degrees. At 24 hours following the second 
injection, the production returned almost to its original level 
or even lower, suggesting that anti-PEG IgM was responsible 
for the ABC phenomenon (Figure 4). However, there was not 
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Figure 1 Effect of the prior injection of solid lipid nanoparticles (SLNs) modified 
with different polyethylene glycol (PEG) surface-densities on the pharmacokinetics of 
a second dose of 10 mol% PEG SLNs in mice. The mice were pre-administered SLNs 
containing 5, 10, and 20 mol% mPEG2000-DSPE [N-(carbonyl-methoxypolyethylene-
glycol-2000)-1,2-distearoyl-sn-glycero-3-phosphoethanolamine] at a dose of 10 µmol 
phospholipids ⋅ kg−1. Seven days later, 10 mol% PEG SLNs were injected intravenously 
at the same dose. Mice pretreated with an injection of glucose served as controls. 
Notes: Data are shown as mean plus or minus standard deviation; mice were 
randomly divided into four groups of five.
However, the subsequent dose, as the effectuation phase 
in the ABC phenomenon,6 was independent of this effect. 
Therefore, as long as it can determine the extent of the 
induced ABC phenomenon, the influence of the first dose is 
better studied even if subsequent doses are different. In this 
study, the ratio of AUC(0–t) for the second injection to that 
of the first injection was selected as the ABC index, used to 
evaluate the phenomenon, and a higher index meant a weaker 
induction of the ABC phenomenon.8 The authors calculated 
the ratio for the different time intervals, which showed 
that the ABC index exhibited significant difference within 
30 minutes following the second injection (Table 4), and the 
discrepancies in the ratio basically remained unchanged until 
24 hours after the second injection (data not shown). These 
results imply that the ABC effect lasted only a short time, and 
the ratio of AUC(0–30 min) (ie, area under the concentration-time 
curve from time 0 to 30 minutes) was suitable for evaluating 
this phenomenon. Also, the ABC level induced by SLNs 
was, in descending order. 10, 20, and 5 mol% PEG SLNs, 
and 10 mol% PEG SLNs induced the most marked ABC 
phenomenon in beagles, which is consistent with the results 
obtained in mice.
The physical state of the beagles was not influenced 
by the quantities of blood collected. In addition, the single 
treatment with PEGylated SLNs did not produce any 
  visible anaphylactic reaction. However, upon subsequent 
administration, noticeable hypersensitive reactions were 
observed in the beagles. Symptoms developed within 
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Figure 2 hepatic (A) and splenic (B) accumulation of the PEGylated solid lipid 
nanoparticles (SLNs) in mice at different time intervals after the second injection. 
The mice were pre-administered SLNs containing 5, 10, and 20 mol% mPEG2000-DSPE 
[N-(carbonyl-methoxypolyethylene-glycol-2000)-1,2-distearoyl-sn-glycero-3-
phosphoethanolamine] at a dose of 10 µmol phospholipids ⋅ kg−1. Seven days later, 
10 mol% polyethylene glycol (PEG) SLNs were intravenously injected at the same 
dose. Mice pretreated with an injection of glucose served as controls. 
Notes: Data are shown as mean plus or minus standard deviation; P-values apply to 
difference between control and treated mice; *P , 0.05; **P , 0.01; ***P , 0.001; 
mice were randomly divided into four groups of five.
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a complete correlation between the level of anti-PEG IgM 
and the extent of the ABC phenomenon induced: the level of 
IgM generated by 10 mol% PEG SLNs was not higher than 
that generated by 20 mol% PEG SLNs.
Discussion
The authors studied the ABC phenomenon induced by 
PEGylated SLNs and, in this study, selected the beagle as 
an experimental animal for the first time. The PEGylated 
SLNs were found to trigger this phenomenon in both mice 
and beagles upon repeated injection, with different intensi-
ties of the ABC phenomenon being observed between the 
two different animal species. The ABC phenomenon was 
mostly an immune response and so the nanocarriers were 
eliminated rapidly when this unexpected phenomenon was 
induced, owing to the fact that the immune response was 
elicited immediately when the pathogen and antibody came 
into contact. Because of this, blood samples were required to 
be densely collected in a short period of time after the second 
injection. The beagle has a high blood volume, which protects 
their physical function when collecting many blood samples 
over a short time period – more so than other experimental 
animals such as mice, rats, and rabbits. Furthermore, the 
beagle is an excellent model when monitoring of hypersen-
sitive reactions is required during the experimental process; 
again, this is often difficult in other experimental animals 
such as mice, rats, and rabbits. Therefore, the beagle is an 
excellent model for examining the induction of the ABC 
phenomenon.
The prolonged circulation time in the blood is the most 
important characteristic of the PEGylated nanocarriers, 
and the PEG surface density is thought to be the key factor 
determining this extended circulation time.36 However, 
despite extensive studies on the ABC phenomenon, it remains 
unclear whether the circulation time affects the induction of 
this phenomenon. Due to the ABC effect lasting only a short 
time, the AUC(0–30 min) ratio was used in the present study as 
an ABC index to evaluate the extent of the phenomenon, and 
the results demonstrated that a marked ABC phenomenon was 
induced only when the PEGylated SLNs exhibited a more 
prolonged circulation time (Table 4). Previous studies have 
reported that PEGylated nanocarriers might elicit an anti-PEG 
IgM response in a T-cell-independent manner and appear 
to be T-cell–independent type 2 antigens24,25 – the surface-
modified PEG might act as an antigenic epitope. For most 
T-cell–independent type 2 antigens, the prolonged contact of 
the antigens with membrane immunoglobulin and persistent 
B-cell signaling is common in inducing a humoral immune 
response in the absence of helper T cells.37,38 Consequently, in 
addition to the density of PEG, it is rational to speculate that 
extended circulation time also plays an important role in the 
induction of the ABC phenomenon. Regarding 5 mol% PEG 
SLNs, because of the only slightly prolonged circulation time, 
inefficient contact of the PEGylated SLNs with membrane 
immunoglobulin stimulated B-cells and resulted in secretion of 
a small amount of anti-PEG IgM, with only a weaker immune 
response and insignificant ABC phenomenon. The 20 mol% 
PEG SLNs exhibited an even more prolonged circulation time, 
and should have resulted in producing a larger quantity of 
anti-PEG IgM, while the results show that the 20 mol% PEG 
SLNs and the 10 mol% PEG SLNs induced subequal amounts 
of anti-PEG IgM. After PEGylated SLNs exhibited a clearly 
prolonged half-life, the authors speculated that the circulation 
time was no longer a determinant in this phenomenon, and the 
Table 4 The main pharmacokinetic parameters of the injected PEGylated solid lipid nanoparticles (SLNs) in beagles
Injected dose AUC(0–24 h) (mg/L*h) CL (L/h/kg) T1/2 β (h) ABC indexa
AUC(0–30 min) AUC(0–24 h)
5 mol% PEG SLNs
  First dose   15.254 ± 1.167 0.050 ± 0.008 1.292 ± 0.123 0.802 ± 0.072** 0.752 ± 0.050***
  Second dose   11.632 ± 0.942 0.066 ± 0.005 1.126 ± 0.092
10 mol% PEG SLNs
  First dose   90.554 ± 8.512 0.010 ± 0.011 3.411 ± 0.379 0.490 ± 0.040## 0.376 ± 0.025###
  Second dose   34.043 ± 3.498 0.025 ± 0.019 1.604 ± 0.026
20 mol% PEG SLNs
  First dose 136.940 ± 11.233 0.006 ± 0.001 4.192 ± 0.278 0.600 ± 0.094*,# 0.489 ± 0.037***,###
  Second dose   67.097 ± 8.940 0.012 ± 0.007 3.395 ± 0.237
Notes: aThe ABC index was calculated as AUC(0–t) of the second dose/AUC(0–t) of the first dose; *P , 0.05; **P , 0.01; ***P , 0.001 represent a significant difference 
compared with 10 mol% PEG SLNs; #P , 0.05; ##P , 0.01; ###P , 0.001 represent a significant difference compared with 5 mol% PEG SLNs; the beagles were randomly 
divided into three groups of three. 
Abbreviations: ABC, accelerated blood clearance; AUC(0–24 h), area under the concentration-time curve from time 0 to 24 hours; AUC(0–30 min), area under the concentration-time 
curve from time 0 to 30 minutes; AUC(0–t), area under the concentration-time curve from time 0 to the last measured concentration; CL, total body clearance; PEG, polyethylene 
glycol; T1/2 β, mean elimination half-life.
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membrane reordering,39 leading to the 20 mol% PEG SLNs 
being able to induce an ineffective immune response and a 
relatively attenuated ABC, consistent with other reports in 
the literature.29
In this study, the authors initially proposed that a relatively 
extended circulation time of the initial dose of PEGylated 
SLNs might be the major underlying factor determining 
induction of the ABC phenomenon. The 10 mol% PEG SLNs 
mostly exhibited a suitable circulation time in this study 
and they effectively stimulated B cells; thus, the activated 
B cells secreted a great deal of anti-PEG IgM, consequently 
binding IgM to the sequentially injected PEGylated SLNs 
and resulting in the 10 mol% PEG SLNs producing a marked 
ABC effect. While a study by Laverman et al6 showed that the 
circulation time of liposomes did not influence the induction 
of ABC, it should be noted that conventional liposomes of 
different particle sizes were employed to evaluate the effect 
of the circulation time in the Laverman et al6 study, while 
it is not known in the present study whether conventional 
nanocarriers and PEGylated nanocarriers exhibited the same 
mechanism for this phenomenon.
Conclusion
The PEGylated SLNs were found to induce the ABC 
phenomenon upon repeated injection, both in mice 
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Figure 3 Effect of mPEG2000-DSPE [N-(carbonyl-methoxypolyethylene-glycol-2000)-1, 
2-distearoyl-sn-glycero-3-phosphoethanolamine] content in solid lipid nanoparticles 
(SLNs) on the induction of accelerated blood clearance phenomenon in beagles. The 
beagles were first administered SLNs containing (A) 5, (B) 10, and (C) 20 mol% 
mPEG2000-DSPE, at a dose of 2 µmol phospholipids ⋅ kg−1. Seven days after the first 
injection, the beagles were given the second injection at the same dose. 
Notes: Data are shown as mean plus or minus standard deviation; the beagles were 
randomly divided into three groups of three. 
Abbreviation: PEG, polyethylene glycol.
PEG surface density, referred to as the density of the antigenic 
epitope in the ABC phenomenon, began to play a decisive role 
in inducing this immune response. Excessive cross-linking 
of membrane immunoglobulin induced by the higher surface 
density of PEG resulted in the receptor rearrangement and 
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Figure 4 Anti-polyethylene glycol (PEG) immunoglobulin M responses following a 
single intravenous injection of PEGylated solid lipid nanoparticles (SLNs) in beagles. 
The beagles were administrated with SLNs containing 5, 10, and 20 mol% mPEG2000-
DSPE  [N-(carbonyl-methoxypolyethylene-glycol-2000)-1,2-distearoyl-sn-glycero-3- 
phosphoethanolamine].  Seven  days  later,  blood  was  withdrawn  and  serum  was 
collected. The serum was also collected at 24 hours after a second injection. 
Notes: The amount of anti-PEG immunoglobulin M antibody was determined as 
described in the “Material and methods” section; each value represents the mean 
plus or minus standard deviation; P-values apply to differences against the control 
(naïve serum); *P , 0.05; **P , 0.01; ***P , 0.001; the beagles were randomly 
divided into three groups of three.
Abbreviation: OD, optical density.
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and in beagles. In addition, the authors found the beagle 
to be the most suitable model for examination of the ABC 
phenomenon. Another major factor determining the induc-
tion of the ABC phenomenon may be the circulation time of 
PEGylated SLNs, although further investigation of a defined 
range of circulation times over which the ABC phenomenon 
would not be induced is needed. These findings may provide 
new perspectives in our understanding of the mechanism of 
the ABC phenomenon.
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